or Try an Advanced Search...

    Technical Analysis for ANRO - Alto Neuroscience, Inc.

    Grade Last Price % Change Price Change
    C 14.36 -0.90% -0.13
    ANRO closed down 0.9 percent on Friday, July 26, 2024, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong N/A Up Down
    Historical ANRO trend table...
    Date Alert Name Type % Chg
    1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Calm After Storm Range Contraction -0.90%
    Wide Bands Range Expansion -0.90%
    Calm After Storm Range Contraction -2.78%
    Older End-of-Day Signals for ANRO ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 10 hours ago
    Possible Inside Day about 10 hours ago
    Down 2 % about 14 hours ago
    Down 1% about 14 hours ago
    Up 1% about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ANRO Chart by TradingView
    Basic chart:

    Profile

    Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Post Traumatic Stress Disorder Electroencephalography Neurocognition Ptsd

    Is ANRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 25 Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
    Jul 16 Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
    Jun 20 Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
    Jun 18 Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
    May 29 Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
    May 21 Alto Neuroscience appoints Michael Hanley as COO
    May 21 Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
    May 15 Alto Neuroscience reports Q1 GAAP EPS of -$0.76
    May 14 Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
    May 9 Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
    See more ANRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.0
    52 Week Low 9.4
    Average Volume 133,910
    200-Day Moving Average 0.00
    50-Day Moving Average 12.50
    20-Day Moving Average 13.59
    10-Day Moving Average 15.03
    Average True Range 1.01
    RSI (14) 56.90
    ADX 35.21
    +DI 26.70
    -DI 13.42
    Chandelier Exit (Long, 3 ATRs) 14.52
    Chandelier Exit (Short, 3 ATRs) 12.43
    Upper Bollinger Bands 16.89
    Lower Bollinger Band 10.30
    Percent B (%b) 0.62
    BandWidth 48.52
    MACD Line 0.79
    MACD Signal Line 0.75
    MACD Histogram 0.0395
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.13
    Resistance 3 (R3) 15.17 14.95 15.00
    Resistance 2 (R2) 14.95 14.76 14.93 14.95
    Resistance 1 (R1) 14.66 14.64 14.55 14.62 14.91
    Pivot Point 14.44 14.44 14.39 14.42 14.44
    Support 1 (S1) 14.15 14.25 14.04 14.11 13.81
    Support 2 (S2) 13.93 14.13 13.91 13.77
    Support 3 (S3) 13.64 13.93 13.72
    Support 4 (S4) 13.60